Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 18, 2007. The document serves as a notification of a major interest in the company's ordinary shares, received from Legal & General Group plc on December 17, 2007, and filed in accordance with Disclosure and Transparency Rule (DTR) 5.8.12.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report is strictly a regulatory disclosure regarding shareholding thresholds and does not contain financial performance data.
Material Changes
The material change reported is an acquisition of voting rights by Legal & General Group plc and its subsidiaries, causing their total holding to cross the 5% threshold.
- Previous Position: Below 5% (262,702,444 shares representing 4.769% direct voting rights).
- Resulting Position: Above 5% (283,832,153 total voting rights representing 5.15% of the total voting rights).
- Transaction Date: December 12, 2007.
- Notification Date: December 17, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The only risk or contingency noted is an administrative delay in the notification process. The filer stated the delay was due to a "large number of disclosures required following a substantial amount of new business which has come to us in the form of an in-specie transfer."
Investor Verification Checklist
- Verify the total voting rights base used for the percentage calculation (stated as 5,507,831,537).
- Confirm the breakdown of direct versus indirect holdings within the Legal & General Group structure.
- Check subsequent filings to determine if the 5% threshold was crossed again or if further acquisitions occurred.
- Note that this filing does not reflect operational or financial performance for the period.